Associate ProfessorDarren Henstridge

Interim Head, School of Health Sciences

Office of the School of Health Sciences

  • Interim Head, School of Health Sciences
    Office of the School of Health Sciences
  • +61 3 6324 3263 (Work)
  • School of Health Sciences, Health Sciences, 103 C, Newnham Campus, TAS

RESEARCH SUMMARy

Fields of Research:
Cell metabolism (310103)
Signal transduction (310111)
Endocrinology (320208)
Animal physiology - systems (310910)
Systems physiology (320803)
Cardiology (incl. cardiovascular diseases) (320101)
Medical biochemistry - lipids (320504)
Gastroenterology and hepatology (320209)
Exercise physiology (420702)


Research Objectives:
Clinical health (200199)
Treatment of human diseases and conditions (200105)
Prevention of human diseases and conditions (200104)
Expanding knowledge in the biological sciences (280102)
Expanding knowledge in the biomedical and clinical sciences (280103)
Expanding knowledge in the health sciences (280112)
Diagnosis of human diseases and conditions (200101)
Overweight and obesity (200411)
Women's and maternal health (200509)

FUNDED PROJECTS

  • GRANT
    Acquisition of a high-frequency ultrasound platform to supercharge discovery research in Tasmania
    1 Jan 2027 - 31 Dec 2029
    People funded by this grant:
    • Premilovac D,
    • Sutherland B,
    • Young K,
    • Flies A,
    • Guven N
    Project Total: $141,000; This equipment grant application to the Ian Potter Foundation will lead to acquisition of a new, purpose built and state of the art ultrasound machine for preclinical work. Currently available machines at UTAS are clinical machines and are not able to adequately support preclinical imaging due to temporal and spatial resolution limits. This new machine will enable live in vivo imaging of any organ in the rat/mouse/zebra fish, measurement of cardiovascular function, targeted drug delivery using microbubbles (contrast agents) and an ultrasound guided micro-injection platform for delivery of compounds or genetic material without off target effects. Funded by: Ian Potter Foundation - Grant - Medical Research ($141,000); University of Tasmania ($141,000).
  • CONSULTANCY/CONTRACT RESEARCH
    RSV Vaccination in Vulnerable Populations (REVULPOP)
    1 Jul 2026 - 31 Dec 2028
    People funded by this grant:
    • Henstridge D,
    • Flanagan K,
    • Tran TMT,
    • O'Connor M,
    • Plebanski M
    Project Total: $136,000; Respiratory syncitial virus (RSV) causes significant morbidity and mortality globally, particularly in early life and older age. Several RSV vaccines have recently been developed and two were approved for use in Australia in 2024. Abrysvo is recommended for use in pregnant women at 28-36 weeks' gestation to protect their newborn child in their first 6 months of life. Abrysvo was recently made available for pregnant women on the National Immunisation Program. Arexvy and Abrysvo, have been approved and recommended for use in older individuals. A systems vaccinology approach will be used to interrogate the broad immunological effects of RSV vaccines on the immune system, providing important data for their ongoing development and deployment. Interrogation of global immune responses in those more vulnerable to serious outcomes, and more likely to have suboptimal immune responses, may identify mechanisms and strategies to further optimise RSV vaccines for vulnerable populations. Funded by: Clifford Craig Foundation; Tasmanian Health Service; University of Tasmania.
  • GRANT
    Utilising mRNA technology to study fatty liver disease.
    15 Feb 2026 - 30 Jun 2027
    People funded by this grant:
    • Henstridge D,
    • Shackel N,
    • Myers S
    Project Total: $44,698; This project aims to utilise a new method called messenger RNA (mRNA) technology to study the effects of a protein that may be protective in fatty liver disease. Specifically, we aim to: Source primary human liver cell lines from patients with various degrees of fatty liver disease. Develop tools to be able to harness mRNA Technology in the laboratory. Deliver our mitochondrial protein of interest using mRNA technology to the patient derived liver cells and assess the effects on liver function and metabolism. Funded by: Clifford Craig Foundation - Expression of Interest ($44,698); University of Tasmania.
  • GRANT
    Purchase of a ChemiDoc MP Imaging System
    1 Jul 2025 - 30 Jun 2026
    People funded by this grant:
    • Henstridge D
    Project Total: $35,000; We are requesting funding to support the purchase of a ChemiDoc MP Imaging System which is a full-feature multi-purpose laboratory instrument for imaging and analysing gels and western blots. Its applications include identifying and quantifying proteins, nucleic acids and protein-ligand interactions. It is designed to address needs for multiplex fluorescent western blotting, chemiluminescence detection, general gel documentation applications and stain-free technology imaging needs. This request is to replace an outdated, faulty and irreparable piece of current equipment that is no longer in working condition (purchased in 2004). There is currently no alternative piece of equipment available in Northern Tasmania. This has drastically impacted research progression for HDR students and led to the waste of a considerable quantity of reagents, consumables, time, and money. Nearly all disciplines of biomedical sciences will find a use for such equipment. The instrument will be used in learning and teaching activities and in research projects. Consequently, it will have dual roles in providing education to the future health and medical workforce and contributing to novel discoveries in the medical research space. Funded by: Perpetual Trustees - IMPACT Philanthropy Application Program ($35,000); University of Tasmania ($21,425).
  • GRANT
    Uncovering the role of the mitochondria gene ACAD10 in metformin action and fatty liver disease.
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Henstridge D,
    • Myers S,
    • Shackel N
    Project Total: $22,714; The Clifford Craig Foundation has opened their expression of interest process for the 2023 granting round. Successful applicants will then be advised to proceed with a full application. This project follows from previous work investigating the role of the mitochondrial gene Acyl-Co-A dehydrogenase family member 10 (ACAD10) in metabolic action. This study will utilise human liver cells in cell culture to assess whether altering the expression levels of ACAD10 improves the ability of the anti-diabetic drug metformin to perform its signalling actions in liver cells. It will also investigate the effect of lipid oversupply to simulate hepatic steatosis and decipher whether ACAD10 could be used to decrease the pathological effect of a high lipid environment on liver cells. Funded by: Clifford Craig Foundation - Grant ($22,715); University of Tasmania.
  • GRANT
    Activating ACAD10 to improve metformin performance.
    1 Jan 2020 - 22 Sep 2022
    People funded by this grant:
    • Henstridge D,
    • Watt K
    Project Total: $58,527; This study sets out to determine whether increasing the protein ACAD10 can be used as a strategy to improve the effectiveness of the drug metformin for maintaining blood glucose levels. Funded by: Diabetes Australia Research Program - Grant ($58,527); University of Tasmania.
  • GRANT
    What drives the regulation of the zinc transporter ZIP7 in insulin-resistant skeletal muscle? Implications for the treatment of insulin resistance and type 2 diabetes.
    1 Jan 2020 - 1 Nov 2021
    People funded by this grant:
    • Myers S,
    • Sohal S,
    • Henstridge D,
    • Mulford J,
    • Fettke G
    Project Total: $17,607; Insulin resistance (IR) is a disorder where cells do not respond to insulin and therefore glucose and fat metabolism are compromised. IR is present before, and contributes to, the development of type 2 diabetes (T2D) and several pathological conditions and complications including blindness, neurodegenerative disease, heart disease, kidney failure, amputations and reduced quality of life. Despite extensive research, there is challenging uncertainty of the molecular mechanisms of IR. Recently, we have published a role for zinc and the zinc transporter protein ZIP7 in control of glucose metabolism in IR skeletal muscle. However, a major 'gap' in this work is the lack of understanding of how ZIP7 is regulated in IR. Delineating how ZIP7 is regulated is highly significant to understand how this zinc transporter might be targeted pharmacologically and lead to clinical interventions for the treatment of IR. Accordingly, we hypothesise that ZIP7 modulates cellular pathways that control glucose metabolism in IR skeletal muscle and is therefore amendable to clinical intervention for the treatment of IR. Funded by: Clifford Craig Foundation - Grant ($17,607); University of Tasmania.
  • GRANT
    Does ACAD10 mediate the metabolic effects of Metformin?
    1 Mar 2018 - 31 Dec 2020
    People funded by this grant:
    • Henstridge D
    Project Total: $59,737; This study sets out to determine whether loss of or decreasing the protein ACAD10 impairs the performance of metformin on controlling blood glucose levels. Funded by: Diabetes Australia Research Program - Grant ($59,737); University of Tasmania.
  • NON-UTAS AFFILIATED
    Targeting heat shock proteins in Alzheimer's Disease
    Shine on Foundation1 Jan 2018 - 31 Dec 2020
    People funded by this grant:
    • Henstridge D
    Project Total: $300,000; Funded by: Shine on Foundation